Head-to-head · WeighScore
Aquivia Health vs PlexusDx
The verdict
Aquivia Health takes it — 72.2/100 to 67.7/100.
Aquivia Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Aquivia Health is a clinician-led, self-pay telehealth platform offering compounded GLP-1 therapy with the option to step up to branded Ozempic or Zepbound — an unusual side-by-side most compounded…
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Aquivia Health | PlexusDx |
|---|---|---|
| WeighScore | 72.2/100 | 67.7/100 |
| Grade | C | C |
| Scorecard rank | #81 | #158 |
| Semaglutide | $149/mo | $149/mo (starting dose, compounded) |
| Tirzepatide | $179/mo | $249/mo (starting dose, compounded) |
| Coverage | Coverage not published | All 50 states |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #81 · C
Strengths
- Clinical care provided by Open Loop Healthcare Partners, PC — a reused, verified MSO network
- Named leadership: Steven Bishop MD (CMO), Phillip Gray PharmD (Chief Pharmacist), Tom Foster (President)
- Itemized public pricing: compounded semaglutide $149/mo, tirzepatide $179/mo, Ozempic $1,299, Zepbound $1,399
- Both compounded and branded GLP-1s offered side by side — unusual for a compounded provider
- Self-pay model with no insurance required and no separate consultation fee
Where it loses points
- No public list of states served — you must complete intake to learn if your state qualifies
- No named 503A compounding pharmacy partner, limiting licensure verification
- No LegitScript, PCAB, or BBB trust badges visible
- Brand confusion: site schema names 'CatalystMD' while the customer-facing brand is Aquivia Health
- FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database
Graded #158 · C
Strengths
- Licensed providers available in all 50 states
- Range of options including low-cost microdose GLP-1 from $129/mo
- Optional Precision Peptide genetic panel adds a personalization angle
- Independent clinician review via state-licensed telehealth platform
- Compounded medications from state-licensed pharmacies
Where it loses points
- Compounded medications only; no FDA-approved brand options
- Specific compounding pharmacies not named
- Genetic-panel upsell may not add clinical value for everyone
- Tirzepatide pricing from $249/mo is higher than budget rivals
- No insurance accepted
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.